Leap Therapeutics

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass., March 11, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2021.

Leap Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

CAMBRIDGE, Mass., March 2, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.

Leap Therapeutics to Present at Raymond James 43rd Annual Institutional Investors Conference

CAMBRIDGE, Mass., Jan. 24, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.

Leap Therapeutics to Present at B. Riley Securities Oncology Investor Conference

Positive clinical trial results are giving investors a reason to cheer.

Why Leap Therapeutics Stock Is Surging Today

Cardiff Oncology

These clinical-stage biotech stocks are headed in opposite directions today.

These 2 Nasdaq Stocks Are Poised to Make Big Moves Today

Leap Therapeutics Inc (NASDAQ: LPTX) will present updated data from the DisTinGuish Phase 2a study of DKN-01, in combination with tislelizumab in gastric or gastric gastroesophageal junction cancer (G/GEJ). Data will be shared at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

Leap Therapeutics Says DKN-01 Combo Regime Show Compelling Efficacy In Gastric Cancer Patients

CAMBRIDGE, Mass., Jan. 18, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting updated data from the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, in patients with gastric or gastroesophageal junction cancer (G/GEJ), at the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium being held on January 20-22, 2022.

Leap Therapeutics to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ASCO GI Cancers Symposium

Pieris Pharma

These two biotech stocks are set to report key clinical data later this year.

2 Risky Growth Stocks That Could Make You Filthy Rich

Creative Medical Technology Holdings

G Medical Innovations Holdings Ltd

Lixte Biotech

Nuverra Environmental Solutions

SeaChange International

Tellurian

Short squeeze penny stocks to watch right now. The post 7 Short Squeeze Penny Stocks To Buy For Under $5 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Short Squeeze Penny Stocks To Buy For Under $5 Right Now

CAMBRIDGE, Mass., Jan. 5, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.

Leap Therapeutics to Present at H.C. Wainwright BioConnect 2022 Conference

CAMBRIDGE, Mass., Jan. 3, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.

Leap Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

AcelRx Pharmaceuticals

Katapult Holdings

Penny stocks with hight hopes from analysts. The post Top Penny Stocks To Buy According To Analysts & Targets Up To 615% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks To Buy According To Analysts & Targets Up To 615%

Harbor Custom Development, Inc.

Kala Pharmaceuticals

Vertex Energy

Looking for short squeeze penny stocks? Give these 5 a look.

Best Penny Stocks To Buy Now For A Short Squeeze? 5 To Watch

Shares of this small oncology company have risen by 45% over the past three months, yet are down 10% over the past month.

Leap Therapeutics: What Prompted Prioritizing This Precision Oncology Company?

Diffusion Pharmaceuticals

iBio

Check these three biotech penny stocks out for your list this month The post Hot Biotech Penny Stocks to Watch As New Variant Creates Volatility appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Biotech Penny Stocks to Watch As New Variant Creates Volatility

CAMBRIDGE, Mass. , Nov. 15, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that members of the senior management team will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference, taking place on Monday, November 29 – Thursday, December 2, 2021.

Leap Therapeutics to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference

CAMBRIDGE, Mass., Nov. 12, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2021.

Leap Therapeutics Reports Third Quarter 2021 Financial Results

Leap Therapeutics, Inc. (LPTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Leap Therapeutics, Inc. (LPTX) Q3 Earnings Expected to Decline

BEST Inc - ADR

GSX Techedu Inc.

Lordstown Motors

Are these the top penny stocks to watch for a short squeeze? The post Best Short Squeeze Penny Stocks To Buy?

Best Short Squeeze Penny Stocks To Buy? 4 To Watch Right Now

LPTX has shown that it can surge on positive data.

Leap Therapeutics: Another Leap Coming Up

These two tiny drugmakers might be hidden gems.

2 Penny Stocks That Could Soar Soon

Leap Therapeutics is an early stage oncology company with a single active asset. Their single asset focuses on a pathway that is dysregulated in multiple cancers.

Leap Therapeutics: All On The Line

Honest Co

DigitalBridge Group

Multiplan Corp

Zeta Global Holdings Corp

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Buy-Rated, Scorching-Hot Stocks All Trading Under $10

Bellus Health Inc

Kadmon Hlds

Find out why last month was a big one for these three drugmakers.

3 Biotech Stocks That Surged in September

AstraZeneca

Leap Therapeutics Inc. ( LPTX , Financial) lived up to its name when it scored a big jump in stock price following its presentation at the recent European Society for Medical Oncology meeting. The Cambridge, Massachusetts-based microcap saw its shares climb 23% to $2.3650 after it reported new data from the study of its drug for treating gastroesophageal junction cancer.

Leap Therapeutics, AstraZeneca Shares Get Boost From Cancer Presentations

News for Leap Therapeutics Stock (LPTX)